Table 2.

Safety and tolerability. Incidence of commonly occurring adverse events occurring at any time during the study (reported in≥25% of patients overall)

	Arm 1 (n= 14)		Arm 2 (n= 12)		Arm 3A (n=16)		Arm 3B (n=5)		Arm 4 (n= 12)		Total (n=59)
	Any grade (%)	Grade 3/4	Any grade (%)	Grade 3/4	Any grade (%)	Grade 3/4	Any grade (%)	Grade 3/4	Any grade (%)	Grade 3/4	Any grade (%)
Diarrhea	11 (79%)	3/0	11 (92%)	-	15 (94%)	3/0	5 (100%)	5/0	10 (83%)	1/0	52 (88%)
Fatigue	12 (86%)	3/0	10 (83%)	3/0	15 (94%)	6/0	5 (100%)	2/0	10 (83%)	2/0	52 (88%)
Nausea	8 (57%)	1/0	4 (33%)	-	11 (69%)	1/0	5 (100%)	1/0	8 (67%)	-	36 (61%)
Hypertension	9 (64%)	-	6 (50%)	2/0	5 (31%)	-	1 (20%)	-	9 (75%)	1/0	30 (51%)
Vomiting	5 (36%)	1/0	3 (25%)	-	12 (75%)	2/0	4 (80%)	1/0	6 (50%)	-	30 (51%)
Neutropenia	10 (71%)	6/0	5 (42%)	1/3	8 (50%)	2/3	1 (20%)	1/0	3 (25%)	1/2	27 (46%)
Anorexia	7 (50%)	-	8 (67%)	-	5 (31%)	-	2 (40%)	-	3 (25%)	-	25 (42%)
Decreased weight	5 (36%)	-	3 (25%)	-	6 (38%)	-	3 (60%)	-	4 (33%)	-	21 (36%)
Leukopenia	6 (43%)	2/0	4 (33%)	3/1	6 (38%)	1/3	1 (20%)	1/0	3 (25%)	2/0	20 (34%)
Dehydration	4 (29%)	-	5 (42%)	1/0	5 (31%)	-	3 (60%)	1/0	2 (17%)	-	19 (32%)
Dyspnea	5 (36%)	-	3 (25%)	-	7 (44%)	1/0	1 (20%)	-	2 (17%)	-	18 (31%)
Abdominal pain	6 (43%)	-	2 (17%)	1/0	6 (38%)	1/0	-	-	2 (17%)	1/0	16 (27%)
Headache	2 (14%)	-	3 (25%)	1/0	3 (19%)	-	1 (20%)	-	7 (58%)	-	16 (27%)
Alopecia	-	-	5 (42%)	-	5 (31%)	-	2 (40%)	-	3 (25%)	-	15 (25%)
Constipation	5 (36%)	-	5 (42%)	-	7 (44%)	-	-	-	1 (8%)	-	15 (25%)

Arm 1: cediranib+mFOLFOX6; arm 2: cediranib+docetaxel; arm 3A: cediranib+irinotecan; arm 3B: cediranib + irinotecan and cetuximab; arm 4: cediranib+pemetrexed